No Data
Contineum Therapeutics Analyst Ratings
RBC Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $31
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy From RBC Capital
Contineum Therapeutics Completes Enrollment In Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis; The Last Patient Is Expected To Complete The Trial In Q3 2025
Express News | Contineum Therapeutics Completes Enrollment in Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)
Express News | RAPT Therapeutics Inc - William Rieflin Steps Down as Chair, Remains Consultant
No Data
